Literature DB >> 20140781

Myasthenia gravis developing in a patient with CNS lymphoma.

Rami Masroujeh1, Zaher K Otrock, Bassem Yamout, Mark N Jabbour, Ali Bazarbachi.   

Abstract

A patient was initially diagnosed with right basal ganglia lymphoma causing left hemiparesis. His disease was resistant to intravenous methotrexate, so he received radiation therapy with remarkable regression of the mass. However, 6 months after his initial diagnosis, he developed symmetric weakness of the proximal muscles. Electromyography was consistent with myasthenia gravis and anti-acetylcholine receptor antibodies were elevated. Treatment with pyridostigmine and corticosteroids improved his symptoms. The residual lymphoma was further treated with rituximab and temozolomide with complete resolution. Pyridostigmine and corticosteroids were stopped after 14 months of initiation with good results. Our case is the first case report of paraneoplastic myasthenia gravis developing in a patient with primary CNS lymphoma. The diagnosis of paraneoplastic myasthenia should be considered in patients with CNS lymphoma who develop muscle weakness and speech problems.

Entities:  

Mesh:

Year:  2010        PMID: 20140781     DOI: 10.1007/s12185-010-0503-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  15 in total

1.  Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil.

Authors:  Steven Vernino; Diva R Salomao; Thomas M Habermann; Brian P O'Neill
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

Review 2.  Primary CNS lymphoma.

Authors:  Fred H Hochberg; Joachim M Baehring; Ephraim P Hochberg
Journal:  Nat Clin Pract Neurol       Date:  2007-01

3.  Association of myasthenia gravis with extrathymic Hodgkin's lymphoma: complete resolution of myasthenic symptoms following antineoplastic therapy.

Authors:  L E Abrey
Journal:  Neurology       Date:  1995-05       Impact factor: 9.910

4.  Posttransplant primary CNS lymphoma.

Authors:  T G Phan; B P O'Neill; P J Kurtin
Journal:  Neuro Oncol       Date:  2000-10       Impact factor: 12.300

5.  Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas.

Authors:  A Cingolani; R Gastaldi; L Fassone; F Pierconti; M L Giancola; M Martini; A De Luca; A Ammassari; C Mazzone; E Pescarmona; G Gaidano; L M Larocca; A Antinori
Journal:  J Clin Oncol       Date:  2000-10-01       Impact factor: 44.544

6.  Central nervous system Hodgkin's lymphoma without systemic manifestation: case report and review of the literature.

Authors:  U Herrlinger; K Klingel; R Meyermann; R Kandolf; E Kaiserling; R D Kortmann; A Melms; M Skalej; J Dichgans; M Weller
Journal:  Acta Neuropathol       Date:  2000-06       Impact factor: 17.088

7.  The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis.

Authors:  Janet E Olson; Carol A Janney; Ravi D Rao; James R Cerhan; Paul J Kurtin; David Schiff; Richard S Kaplan; Brian Patrick O'Neill
Journal:  Cancer       Date:  2002-10-01       Impact factor: 6.860

8.  Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma.

Authors:  Ajeet Gajra; Neerja Vajpayee; Sara J Grethlein
Journal:  Am J Hematol       Date:  2004-10       Impact factor: 10.047

9.  [Myasthenic syndrome associated with relapse of Hodgkin's disease].

Authors:  M A Lastowska
Journal:  Acta Haematol Pol       Date:  1994

Review 10.  Paraneoplastic myasthenia gravis: immunological and clinical aspects.

Authors:  G O Skeie; F Romi
Journal:  Eur J Neurol       Date:  2008-08-20       Impact factor: 6.089

View more
  1 in total

Review 1.  Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.

Authors:  Raffaele Iorio; Valentina Damato; Paolo Emilio Alboini; Amelia Evoli
Journal:  J Neurol       Date:  2014-10-12       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.